Ocular morbidity in bone marrow and peripheral blood stem cell transplant recipients by Anupriya, Arthur
 
 
 
 
 
 
 
OCULAR MORBIDITY IN BONE MARROW 
 
AND PERIPHERAL BLOOD STEM CELL 
 
TRANSPLANT RECIPIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OCULAR MORBIDITY IN BONE MARROW 
 
AND PERIPHERAL BLOOD STEM CELL 
  
TRANSPLANT RECIPIENTS 
 
 
 
 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment of the MS  
 
Branch III (Ophthalmology) examination of the Tamil Nadu 
 
 Dr MGR Medical University to be held in March 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                               
 
                                                      DECLARATION 
 
 
 
 
 
 
I hereby declare that the investigations that form the subject matter of this thesis was 
carried out by me under the guidance of Dr. Pushpa Jacob, Professor of 
Ophthalmology, Christian Medical College, Vellore. This has not been submitted in 
any other university in part or in full.  
 
 
 
                                                                           Dr. Anupriya Arthur, 
                                                                Department of Ophthalmology, 
                                                                Schell Eye Hospital,  
                                           Christian Medical College, Vellore                              
 
 
Date: 31/8/2004 
Place: Vellore    
 
 
 
 
 
 
 
 
                                                    CERTIFICATE 
 
 
This is to certify that this dissertation entitled “Ocular morbidity in post bone 
marrow and peripheral blood stem cell transplant recipients” is bonafide work done 
by Dr Anupriya Arthur in partial fulfillment of the rules and regulations for      
M.S.Branch III (Ophthalmology) examination of the Tamilnadu Dr MGR Medical 
University, Chennai, to be held in March 2007. 
 
 Dr Pushpa Jacob,     Dr Sharada David 
Professor,        Professor & Head of the Dept 
Dissertation Guide,                             Department of Ophthalmology 
Department of Ophthalmology,    Christian Medical College, Vellore. 
Christian Medical College, Vellore.   
 
 
 
 
 
Date  :31/8/2006 
Place :Vellore   
 
 
 
 
Acknowledgement 
 
 
I would like to express my deep sense of gratitude to my chief guide Dr. Pushpa Jacob, 
Professor Department of Ophthalmology for generating a novel topic for this dissertation 
and for the all the timely advice and much needed help. 
 I am especially grateful to the Department of Haematology especially Dr Mammen 
Chandy, Dr Alok Srivastav, Dr Auro and Dr Vikram for all the help extended for this 
study. 
My sincere thanks to Dr Renu Raju, Dr Andrew Braganza and Dr Sharada David for their 
valuable support. 
My sincere gratitude to Mr. Deenadayalan our Librarian, Mr. Able, Mr. Maydinaselvam 
and Mr Vishwanathan for all the help rendered.  I also take this opportunity to thank the 
MRD staff especially Mr Rajasheker, Mr Sudhakar and Mr Albert for all their help. 
I sincerely thank all my friends and colleagues for their support 
 
To all the patients who were willing to come for the study a big Thank You. 
 
 
          Anu  
 
 
 
 
 
 
 
 
 
 
 
 
  
CONTENTS  
       Page number 
 
1. Introduction      1 
2. Aims        4 
3. Review of literature     5 
4. Materials and methods    32 
5. Results      39 
6. Discussion      54 
7. Conclusions      60 
8. References      61 
 
 
 
 
 
 
 
 
 
 
 
                                                        INTRODUCTION 
 
       The first successful transplantation of allogenic haematopoietic cells was performed 
in 1968 in three children with congenital immune deficiency.1 Since then thousands of 
patients have received haematopoietic stem cell transplantation.  Bone marrow 
transplantation has now become the treatment of choice for a wide variety of 
hematological and non hematological disorders such as aplastic anemia, hematological 
malignancies, transfusion dependent congenital anemias and some metabolic diseases.   
 
The source of stem cells can be from bone marrow, peripheral blood or cord 
blood.  
BMT uses ablation of the patient’s own bone marrow with cytoreductive 
chemotherapeutic agents and with total body irradiation followed by transplantation of 
the donor marrow to reconstitute the patient’s hematologic function.2 The eyes are 
generally not shielded during total body irradiation because they are a potential site of 
leukaemia relapse.  Subsequently the patient has to be maintained on a prolonged 
immunosuppressive regimen to prevent rejection of the transplanted bone marrow.    
          
In general haematopoietic stem cell transplant can be classified into 3 different types3 
1. Allogenic transplant – donor marrow is harvested from HLA compatible donor 
2. Syngenic transplant – donor marrow is harvested from HLA compatible                            
monozygotic twin     
3. Autologous transplant - patients own bone marrow is harvested prior to induction 
therapy and later restored after chemotherapy and total body irradiation has been 
completed. 
 
Complications following BMT are not uncommon and involve various organs like 
lungs, GIT and the eye.  The underlying causes are multifactorial.2    These includes side 
effects of the preparative regimens such as high dose chemotherapy, steroid treatment 
and irradiation as well as graft versus host reaction.4  The major systemic complications 
post transplantation are infections and graft versus host disease (GVHD) which can be 
acute or chronic.    In GVHD the lymphocytes of the immunocompetent donor mount an 
immunological attack on the immunoincompetent host.   Two distinct clinical syndromes 
of GVHD have been described, acute and chronic.  Acute GVHD clinically presents 
within the first 100 days of transplantation as an acute exanthematous dermatitis, enteritis 
and hepatitis.  In contrast chronic GVHD occurs later than 100 days.  It resembles an 
autoimmune illness with scleroderma like involvement of the skin, dacryoadenitis, 
chronic liver dysfunction and profound immunodeficiency2.   
 
Ocular complications following BMT are common.  The most common anterior 
segment complications are keratoconjunctivitis sicca, cataract and corneal ulcers.  
Posterior segment complications include vitreous hemorrhage, microvascular retinopathy, 
optic disc edema and fungal and viral retinitis.  Infectious and hemorrhagic lesions can 
occur as a consequence of transient pancytopenia immediately following the transplant.  
The infectious complications include fungal endophthalmitis, infectious keratitis and 
herpes zoster ophthalmicus.  Hemorrhagic complications include subconjunctival 
hemorrhage and intraretinal and vitreous hemorrhage.5  
Ocular complications are common, but they are often underreported and under 
diagnosed due to lack of awareness and because of other life threatening systemic 
complications that overshadow them.  Even though most of these complications do not 
lead to blindness, they can lead to significant ocular morbidity if appropriate treatment is 
not promptly initiated.       
               There is no data in this field from the Indian subcontinent.  This study aims to 
evaluate the presence of ocular morbidity in patients undergoing bone marrow 
transplantation and peripheral blood stem cell transplantation.  
 
 
 
 
 
 
 
                                                  
 
 
 
  
 
AIMS 
 
To document the presence of ocular morbidity in patients on follow up after bone 
marrow or peripheral blood stem cell transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
 
Allogenic bone marrow transplant is an important treatment option for both 
malignant and non malignant neoplasms of the bone marrow including leukaemias, 
lymphomas and severe aplastic anemia.5 
   
Allogenic bone marrow transplantation (BMT) from an HLA-identical sibling is 
effective therapy for patients with bone marrow failure states and those with hematologic 
malignancies.  However, only a minority of them will have an HLA-identical sibling 
donor.  Unrelated matched or partially mismatched donors have been used successfully 
for patients lacking a related donor.  Even though results with allogenic transplants using 
unrelated donors are encouraging, the incidence of complications including graft-versus-
host disease (GVHD) and graft rejection or late graft failure is increased compared to 
HLA identical sibling transplants.  The combination of cyclophosphamide and total body 
irradiation (TBI) has been used as an effective preparative regimen for allogenic 
transplants.6   By this conditioning regimen the patients own bone marrow is destroyed.  
The purpose of the regimen is to eradicate all malignant cells and to suppress the host 
immune response.  The donor marrow is then transplanted to repopulate the host bone 
marrow thereby re-establishing the haematologic function.  
            
  Depending on the source of the stem cells, transplantation include peripheral 
blood stem cell transplant, bone marrow transplantation and cord blood transplantation 
The technique of BMT consists of sterile removal of bone marrow from the iliac crest.7 
The marrow is intravenously infused into the recipient.  Subsequently the patients are 
maintained on a prolonged immunosuppression to prevent rejection of the transplanted 
bone marrow cells. 
 
           In Peripheral blood stem cell transplantation a variety of mobilization 
techniques are used to increase the number of stem and progenitor cells circulating in the 
peripheral blood.8   After mobilization, an apheresis machine collects the cells. After 
venous blood is collected and processed through the apheresis machine, the nontargeted 
components are returned to the patient.  
      
In general bone marrow transplant can be classified into 3 different types3 
4. Allogenic transplant - using an HLA compatible donor  
5. Syngenic transplant - HLA compatible monozygotic twin is the donor     
6. Autologous transplant - Patients own bone marrow is used.  Prior to induction 
therapy patients marrow is harvested and later restored after chemotherapy and 
TBI has been completed. 
Subsequently following allogenic transplantation the patient has to be maintained 
on a prolonged immunosuppressive regimen to prevent rejection of the transplanted bone 
marrow. 
       
           The major systemic complications post transplantation are infections and graft 
versus host disease.9 
 
Graft versus host disease: 
In graft versus host disease lymphocytes of the immunocompetent donor mount 
an immunologic attack on the now immunoincompetent host.9     GVHD can be of two 
types acute and chronic. 
 
Acute GVHD occurs within hundred days of transplantation in 30 to 60% of 
histocompatible sibling matched allografts.  Mortality directly or indirectly due to acute 
GVHD may reach 50%.  It classically presents as an acute exanthematous dermatitis, 
enteritis or hepatitis.11 
  
Chronic GVHD develops in 30 to 50% of patients approximately 3 to 6 months 
after transplantation.  It resembles an autoimmune illness with scleroderma like 
involvement of the skin, dacryoadenitis, chronic liver dysfunction and profound 
immunodeficiency with recurrent bacterial infections.12  Those at risk for chronic GVHD 
include older patients and those with previous acute GVHD. 
 
Peripheral blood haematopoietic stem cell transplants have been shown to result 
in more rapid engraftment than standard bone marrow transplants and have better 2 year 
survival rates.10  But the rapid engraftment by itself in these transplant recipients                
could lead to chronic GVHD and late systemic fungal and cytomegalovirus (CMV) 
infection.10 
 
Pathogenesis:  
Recognition of allogenic difference by competent immunogenic cells is the 
central event of GVHD.9  GVHD occurs when immunocompetent transplanted marrow 
cells target antigens on the surface of recipient cells. 
 
The first step in the development of GVHD is the recognition of host peptides by 
allotransplanted immune cells.  A co stimulatory signal determines whether peptide 
recognition will lead to full or partial activation of an immunologic response.13   
Secretion of interleukin 2 (IL 2) leads to clonal expansion and proliferation of T cells.  T 
cells and monocytes in turn release cytokines, TNF alpha and interferon gamma which 
recruit other T cells and natural killer cells.14   In support of this both CD4  and CD8    
lymphocytes can be found in GVHD lesions.  
 
Dysregulation of the intrinsic cytokine network is a primary cause for the 
induction and maintancence of GVHD.15 
 
Antin and Ferrara proposed that GVHD after allogenic BMT may be 
pathophysiologically characterized as a cytokine storm comprising three steps.16  The 
initial step involves damage to the host tissue – skin, intestinal mucosa and liver caused 
by radiation and / or chemotherapy during the conditioning regimen leading to the 
production of proinflammatory cytokines such as IL-1 and tumor necrosis factor alpha 
(TNF α).  These in turn cause increased expression of HLA alloantigens and adhesion 
molecules on the surface of the host cells leading to activation and proliferation of mature 
donor T cells. 
 
In the acute or suppurative form of GVHD the principal T cell response is a helper T 
cell type 1 or an inflammatory response with production of IL2 and interferon alpha.  
These cytokines activate additional donor and residual host mononuclear cells and 
macrophages resulting in the secretion of IL1, TNF alpha and other cytokines and 
consequent amplification of the pathogenic cycle. 
  
 The chronic or stimulatory form of GVHD is characterized by increased 
immunoglobulins E synthesis and  exaggerated lymphoproliferative  production of IL4 
and IL10 by helper T cells.    
 
One approach taken to prevent the cytokine storm after allogenic BMT has been 
to deplete donor T cells from the graft before infusion into the host.  Although this 
maneuver reduces the risk of subsequent development of GVHD it concomitantly impairs 
the engraftment of donor cells and increases the risk of relapse of malignancy.  The latter 
phenomenon has been attributed to the depletion of the cell mediating the so called graft 
vs host reaction.   The exact identity of these cells and their relationship to those 
mediating GVHD remains unclear. 
 
 Systemic manifestations: 
GVHD is manifested primarily by symptoms and signs associated with skin, GIT 
and liver.17   Cells reacting in an autoimmune fashion produce abnormal pattern of 
cytokines which stimulate collagen production by fibroblasts.  Both the B and T subsets 
of lymphocytes are altered qualitatively and quantitatively.  However in severe GVHD 
bone marrow suppression may also occur.  60 to 80% of patients with acute GVHD will 
go on to develop chronic GVHD.24  25 % of those who do not  have acute GVHD go on 
to develop chronic GVHD.  Acute and chronic GVHD differs in its distribution of target 
organs and its clinical presentation.18  Acute GVHD primarily affects the skin ,liver and 
GIT.19 
 
Skin 
  Mild acute GVHD of the skin presents as erythema and the severity increases as 
the percentage of body surface area involved increases.  In severe cutaneous acute GVHD 
there is bulla formation and desquamation.  The pathogenesis is immune mediated attack 
on the skin epithelium by the donor lymphocytes. 
 
Staging of skin involvement in acute GVHD  
                  Stage 1 - less than 25% of total body surface area  
                  Stage 2 - 25-50% of total body surface area  
                  Stage 3 - greater than 50% of total body surface area  
                  Stage 4 -  bulla formation 
More than 90% of patients with chronic GVHD have cutaneous abnormality.20 
Two predominant forms have been noted.  One type is similar to lichen planus and the 
other resembles morphea.21 
Liver   
The organ next commonly affected by acute GVHD is the liver.  The earliest 
abnormality is a rise in conjugated bilirubin and the alkaline phosphatase level reflecting 
underlying damage to the bile canaliculi.  In chronic GVHD cholestasis is common. 
GIT 
  Gastrointestinal tract is the third most commonly affected organ.  It can be the 
most severe and is refractory to treatment.   Symptoms include abdominal cramps and 
diarrhea, which may exceed ten liters per day and may result in severe dehydration.  The 
diarrhea is seedy representing epithelial desquamation.  Severe cases can have 
haematochezia.  In chronic GVHD enteritis is uncommon. 20   Secretory diarrhea and fat 
malabsorption can occur. 
 
Clinical staging of liver involvement is based on elevation of liver enzymes and 
bilirubin levels, while staging of GIT involvement is based on volume of diarrhea. 
 
Treatment for systemic GVHD  
Corticosteroids are the mainstay of therapy.  Dosing is titrated according to the 
grade and severity of GVHD.  It can range from one milligramme per kilogramme to 
three milligramme per kilogramme per day.22  Cyclosporine can also be used as primary 
therapy.  Thalidomide has also been described.23  Chronic GVHD if left untreated has an  
overall survival rate of 18% .24 
Prevention of GVHD   
One approach to prevent GVHD is to use antibodies that recognize antigens 
expressed on T cells. With this acute GVHD develops in less than 10% of patients but 
engraftment fails to achieve in 20%.  Another approach is induction of post transplant 
immunosuppression with a combination of Methorexate and Cyclosporine.25  With this 
incidence of GVHD has decreased from 50% to 20%.  
 
Ocular Morbidity in Bone Marrow Transplantation 
.              Ocular morbidity is divided into two groups, depending on whether they occur 
in the acute phase or in the chronic phase.26 
 
Acute phase complications:  
1. Pseudomembranous conjunctivitis 
2. Corneal ulcer 
3. Episcleritis 
4. Secondary choroidal detachment  
5. Secondary glaucoma 
6. Cytarabine induced keratitis   
7. Herpes simplex virus infections  
 
Chronic phase complications: 
1. Dry eye  
2. Meibomian gland dysfunction  
3. Retinal hemorrhages  
4. Aseptic conjunctivitis 
5. Lagophthalmos 
6. Corneal thinning 
7. Corneal melting  
8. Nasolacrimal duct obstruction 
9. Prolonged corneal ulcer 
10. Calcareous corneal degeneration 
11. Optic disc edema 
12. Cotton wool spots 
13. Cataract 
 
Acute Phase complications      
Pseudomembranous conjunctivitis can occur secondary to acute GVHD.  
Conjunctival involvement is a marker for severe systemic involvement in GVHD.  
Conjunctival GVHD presenting with pseudomembrane formation results from loss of the 
conjunctival epithelium.26 
 
Herpes Simplex  keratitis although rare can occur as an infectious complication.  
Approximately 80% of herpes infection involve the oral cavity.  In the eye it tends to 
occur early, usually during the first month after SCT and is due to the result of the virus 
reactivation.   
   
Cytarabine induced keratitis is due to high concentration of the drug in the tears 
It is usually noted four to seven days after commencement of therapy with Cytosine 
arabinoside.27   It presents with symptoms of foreign body sensation, photophobia and 
blurred vision.  The conjunctiva shows hyperaemia and chemosis.  Corneal changes 
varies from refractile epithelial microcysts, central punctate erosions, sub epithelial 
opacities and mild stromal oedema.  Topical steroids are the treatment of choice.  
Steroids are given till all the symptoms and signs disappear. 
 
Chronic phase complications : 
  Meibomian gland dysfunction is frequently associated with severe dry eye and 
is related to chronic GVHD.  The evaluation of meibomian gland dysfunction is helpful 
for the diagnosis of dry eye.28  
                            
Recurrent corneal perforation and acute calcareous degeneration that can be 
recalcitrant to medical and surgical treatment can occur in chronic GVHD as a 
complication of keratoconjunctivitis sicca.29 
 
           Cataract after SCT usually develops within 3 to 5 years. Cataract genesis is 
caused by a combination of pretreatment with antimitotic agents, exposure to radiation 
during the conditioning process and prolonged use of systemic steroids. Cataract is 
usually posterior subcapsular. 
 
Lagophthalmos, corneal thinning, corneal melting, nasolacrimal duct block and  
chronic dacrocystitis can be seen as late complications.  Acute anterior uveitis can 
develop for up to 20 months after transplantation. 
 
Retinal hemorrhages is related to GVHD, vasculopathy, CMV retinitis or 
recurrence of leukemic disease. 
 
Anterior segment complications 
The most common anterior segment complications are keratoconjunctivitis sicca, 
cataract. These are more common in patients in patients with GVHD26 and is described in 
detail later.   
Posterior segment complications  
The common posterior segment complications are vitreous hemorrhage, 
microvascular retinopathy, optic disc edema and fungal and viral retinitis. 
 
Retinal complications of bone marrow transplantation  
            Posterior segment complications are less frequently encountered, but they can 
have significant visual consequences and implications.  About 12% of patients can 
develop posterior segment complications.30 
                                                           
They are of 3 types31 
1. Micro vascular retinopathy  
2. Infection  
3. Hematological complications  
 
Bone Marrow Transplant retinopathy was first reported in 1983.  It usually occurs 
within 6 months of BMT.  It can occur as early as 3 months or as late as 62 months after 
BMT.  Diabetes can facilitate the development of BMT retinopathy by contributing to the 
ischemic microvasculopathy.  There are no known predictors like age, gender and race 
for this complication. 
 
Clinical features of BMT Retinopathy 
Patients present with decreased visual acuity, field deficit or both.  Retinal 
findings are typically bilateral and symmetrical.  Clinical findings include multiple cotton 
wool spots, telangiectasias, microaneurysms, macular edema, hard exudates and retinal 
hemorrhages. 
 
Occlusive microvascular retinopathy has been described after BMT with retinal oedema, 
hemorrhage, soft exudates and neovascularisation in the posterior pole and peripheral 
fundus.  It regresses and cicatrises with oral steroids.  The visual prognosis depends on 
the foveal involvement of the retinopathy.32   Fluorescein angiogram often reveals 
capillary non perfusion and dropouts.  Intraretinal microvascular abnormality, 
microaneurysm and fluorescein leakage around the fovea consistent with macular edema 
can be seen. 
 
Bilateral optic disc oedema may also be present.33,34  This can be due to 
microvascular retinopathy or to cyclosporine induced neurotoxicity. 
  
Pathogenesis:  The exact cause for BMT retinopathy is yet to be ascertained. 
Cyclosporine toxicity, total body irradiation and conditioning chemotherapy have been 
implicated. 
 
Cyclosporine is a potent immunosuppressive agent.  It can cause endothelial cell injury. 
Other side effects are nephrotoxicity, hypertension, seizures, encephalopathy, cortical 
blindness, cerebellar and spinal syndromes and raised intracranial tension.  But it has not 
been demonstrated to cause BMT retinopathy in autologous or syngenic bone marrow 
recipients or in renal transplant patients.  Drugs such as Cisplatin, Carmustin and 
Cyclophosphamide can cause ocular side effects including papillodema, optic neuritis, 
visual field defects and cortical blindness.  Cyclosporine induced retinal toxic blindness 
can occur.35 
 
TBI damages the retinal microvasculature and may lead to ischemic vasculopathy. 
Modifying factors such as total dose of irradiation and the time interval between radiation 
and bone marrow ablation are important.36   The incidence and severity of BMT 
retinopathy correlate with high total body irradiation and a short time interval between 
radiation and BMT.  Therefore irradiation is not the sole factor but it appears to be 
another contributory factor in the development of BMT retinopathy.  
 
BMT retinopathy and radiation retinopathy have similar clinical features 
including multiple cotton wool spots, telangiectasia, microaneurysms, macular edema, 
hard exudates and retinal hemorrhages.  
 
But there are definite differences between the two37 
 1) BMT retinopathy is generally reversible where as radiation retinopathy is progressive. 
In fact BMT retinopathy does not progress beyond the ischemic microvascular stage. 
 2)  Radiation retinopathy is often refractory to treatment.  
3) BMT retinopathy is usually observed within 6 months of BMT but radiation 
retinopathy manifest approximately 18 months after the treatment 
 
Patients with BMT retinopathy usually have a good prognosis – the retinopathy 
typically resolves within 2 to 4 months after cessation or lowering of the dosage of 
cyclosporine with or without the use of systemic prednisolone.  In one report 69% of 
patients had complete resolution of the retinal findings and 46% of patients fully 
recovered their baseline visual acuity.  Because of the relatively favorable prognosis and 
non progressive nature of BMT retinopathy aggressive treatment is not necessary. 
 
Infection 
Infections in the post bone marrow transplant period is a major cause for mortality 
in recipient patients.38 However ocular infections are relatively uncommon after 
haematopoietic stem cell transplantation.  Ocular infections usually affects the posterior 
segment and the incidence is around 2 %. 30 
 
Viral infections : 
CMV retinitis is seen in about 1% of patients after BMT .39 In solid organ 
transplantation the incidence is 2 to 15 %40,41,42,43 Repeated treatment with antithymocyte 
globulin may lead to immune dysfunction that could increase the likelihood of CMV 
retinitis.  Certain immunosuppressive agents such as mycophenolate mofetil has been 
associated with increased risk of systemic CMV infections in BMT.  Visual outcome 
from CMV retinitis can be devastating.44  ln most cases total blindness occurs, and is seen 
in three out of five patients treated adequately with antiviral regimen.  CMV retinitis is 
more in HLA matched unrelated donor transplants than in HLA matched related sibling 
transplants.  It responds well to antiviral agents.  The prophylactic use of Valacyclovir for 
CMV infection in BMT has been proposed.  Treatment is with Foscarnet and intraocular 
injection of Gancyclovir.45 
 
Another cause of viral retinitis is Herpes zoster.46 Clinical features of herpes 
zoster retinitis are similar to those for acute retinal necrosis.  The infection typically 
responds well to intravenous Acyclovir therapy. 
 
 Fungal infections: 
Fungal infection is not an uncommon posterior segment complication.  In one 
study fungal retinitis and endopthalmitis were the most common intraocular infections 
after bone marrow transplantation.  Among them Candida and Aspergillosis are 
common.30 
 
Fungal infections occur early after bone marrow transplantation with a median 
time of fifty seven days.  In solid organ transplants Aspergillus retinitis is more 
common.47,48   The primary focus of Aspergillus is subretinal or subretinal pigment 
epithelium.  Vitreous biopsy may not yield positive results in Aspergillosis.  
Disseminated Fusarium infection with secondary fungal endophthalmitis can occur.49 
 
Toxoplasmic retinochoroiditis 50   
This is a reactivation of the existing ocular toxoplasmosis.  Infection may also 
represent primary ocular disease.  Toxoplasmic retinochoroiditis typically occur within 
three to six months and can be either unilateral or bilateral.  With appropriate antibiotic 
therapy it can usually be controlled.  
 
 
Hematological complications  
In the early post transplant period hematological abnormalities including anemia, 
hyperviscosity syndromes and thrombocytopenia are common due to the bone marrow                                    
aplasia and chemotherapy 51,52  These changes predispose to vitreous hemorrhage, 
intraretinal hemorrhages and other hemorrhagic complications.53,54  Thrombocytopenia is 
the most important factor in the development of hemorrhage.  The incidence is about 
3.5%.  The majority of hemorrhagic complications are observed six months after BMT 
with the median time of 51 days.38 
 
Other complications  : 
Central serous choreoretinopathy (CSCR ) is more common after solid  organ 
transplantation.31  Pathogenesis of CSR is believed to be associated  with combined 
effects of  high dose corticosteroids, emotional stress, systemic hypertension  and 
cyclosporine.  There may be also retinal pigment epithelial changes caused by 
choriocapillaries ischemia leading to serous retinal detachment.  Visual prognosis is 
generally good and the treatment of photocoagulation may be needed only in refractory 
cases. 
 
Bilateral optic disc edema may occur in 2.8%30  Optic disc oedema is due to 
cyclosporine related toxic effects or increased pressure or both.  Cyclosporine induced 
retinal toxic blindness after BMT can occur.55 
 
 
Ocular manifestations of graft versus host disease 
                  Because of other life threatening systemic complications in patients with 
GVHD, ocular manifestations may often be overlooked.  This at least partially explains 
the sparse documentation in literature of ocular complications in this disease.  Ocular 
features occur in approximately 60 to 80% of patients with GVHD.56 Ocular problems are 
uncommon in acute GVHD, however ocular manifestations like keratoconjunctivitis 
sicca, sterile conjunctivitis, cicatricial lagophthalmos, cataracts and retinal micro vascular 
occlusive disease can occur due to chronic GVHD.    
Dry eye associated with chronic GVHD is the most frequent ocular complication after 
SCT (40 - 60%) followed by meibomian gland dysfunction (48%) and retinal hemorrhage 
(35 to 40%).23  GVHD can involve any part of the eye 
Lids57 
1. Dermatitis, acute and chronic 
2. Lagophthalomos   and ectropion from chronic lid inflammation 
3. Loss of cilia 
Lacrimal apparatus: Decreased aqueous secretions 
Conjunctiva 
1. Conjunctivitis 
2. Xerosis secondary to decreased tears 
Cornea 
1. Superficial punctate keratitis 
2. Persistent epithelial defect 
3. Ulceration – infectious / sterile  
 
Uvea  
1. Iritis 
2. Iridocyclitis 
3. Choroiditis 
 Posterior Segment Complications  
1. Microvascular retinopathy, 
2. Intraretinal hemorrhage 
3. Vitreous hemorrhage 
 
Lids  
Lids may be involved as part of the acute or chronic systemic skin changes 
associated with GVHD.  Chronic lid inflammation may lead to lagophthalmos and 
ectropion.  Loss of cilia is common with generalized skin involvement. 
 
 Keratoconjunctivitis sicca 
Dry eye as a result of lacrimal gland dysfunction is one of the commonest 
manifestation of chronic GVHD.   Even in patients with acute GVHD without ocular 
complications there is an increased risk for developing dry eye in the later stages.58   In 
most cases, the severity of the systemic chronic GVHD correlates with the severity of the 
dry eye. 
 
Incidence  
Dry eye after SCT has an incidence of 40 - 60%.23 In a multicentric retrospective 
cohort study dry eye syndrome developed in 19% of patients between 3 and 127 months 
after BMT.  In this study 69% with dry eye syndrome had systemic GVHD, compared 
with 30% without dry eye.59 
 Approximately half the patients who undergo SCT develop dry eye 6 months 
later.26  Severe dry eye resembling Sjogren’s syndrome progress rapidly after the onset of 
symptoms in the majority of these patients.  The median time from transplantation to 
diagnosis of dry eye was 171 ± 5.9 days.26 
 
Pathology   
Lacrimal gland specimens from patients with dry eye show prominent fibrosis, 
increase in CD4 stromal fibroblasts in the glandular interstitium and infiltration of T cells 
in to the periductal areas.60  Periductal fibroblasts are involved in the fibrogenic and 
immune processes by interacting with T cells in the lacrimal gland of patients with 
chronic GVHD resulting in rapidly progressive dry eye. 
 
Activated fibroblasts synthesize an excess amount of extracellular matrix 
resulting in rapid interstitial fibrosis.  On the other hand CD8 lymphocytes which are 
activated through antigen recognition and the helper function aided by CD4 cells   
infiltrate and destroy the duct epithelium.  Multilayered basal lamina of ducts, lobules 
and vessels is seen.  This is the result of repeated damage and repair due to the immune 
process.  The degree of thickening correlates with the severity of dry eye.   
 
Risk factors 
GVHD is the major risk factor for the development of dry eye.9  KCS occurred 
more frequently in patients with chronic GVHD than in those with acute GVHD.  Dry 
eye is observed in patients receiving autologous or syngenic transplants who are not at 
risk for GVHD implying a cause beyond a simple alloreactive immune reaction.61           
  As conditioning regimens, TBI administered as a single dose rather than in 
fractions and chemotherapy alone before BMT, both increase the risk of 
keratoconjunctivitis sicca.61  
 
Clinical Features  
   Dry eye after BMT is clinically similar to Sjogren’s syndrome in that both are 
characterized by decreased lacrimation.  Patients with GVHD have a compromised 
epithelium as a result of lacrimal gland hyposecretion.  They may also have a lower 
threshold for cytotoxicity from radiation or chemotherapy.  Usually patients are 
asymptomatic.  Punctate keratitis, persistent epithelial defects, corneal keratinisation, 
ulceration and perforation may be seen as a sequelae of dry eye.9  
Diagnosis 
           The diagnostic tests for dry eye62-65 is given in the Appendix.  
 
 
Prognosis 
In most patients KCS persists after remission of GVHD.  In one study none of the 
patients had normal tear function in four years of follow up.4   In another study resolution 
of tear function occurred in 8% of affected GVHD patients.66 
 
Conjunctival GVHD 
In a prospective study of 162 patients who had undergone allogenic BMT, Jack 
and co workers reported findings that implicated the conjunctiva and the cornea as 
immunologic targets in GVHD.  Histological examination revealed changes similar to 
those seen in cutaneous GVHD, including lymphocytic migration into the basal 
epithelium of the conjunctiva, presence of dyskeratotic cells and even subepithelial 
microvesicle formation and total separation of the epithelium in more severe cases.5 
The median onset after transplantation was about 14 days after their first 
manifestation of acute GVHD.58 The degree and severity of the conjunctival disease 
tends to correspond with the severity of the systemic disease.  
Jabs and coworkers proposed a system for the clinical staging of conjunctival and 
ocular surface GVHD5 
Stage I :  Characterized by conjunctival hyperemia 
Stage II : Conjunctival hyperemia with the additional findings of a chemotic  
             response or serosanginous exudates  
Stage III : Pseudomembranous conjunctivitis  
Stage IV : Pseudomembranous conjunctivitis with epithelial sloughing  
 
Within days of appearance of acute GVHD, hemorrhagic conjunctivitis similar to 
that of viral hemorrhagic conjunctivitis may be noted.  This finding often occurs in 
patients who are morbidly ill from acute GVHD.  Hemorrhagic conjunctivitis is followed 
by the development of purulent conjunctivitis within three to four days.  Though 
numerous polymorphonuclear leucocytes are present bacterial, fungal and viral cultures 
are generally sterile.  During this exudative phase, upper tarsal ulceration can be 
observed.  There is scarring of the conjunctiva following resolution of the inflammatory 
changes.  In some cases, conjunctival scarring may be found in patients without 
exudative or ulcerative conjunctivitis.   Furthermore massive filamentary keratitis and 
sloughing of the corneal epithelium similar to those seen in massive recurrent corneal 
erosion can occur in patients with acute GVHD. 
          
 Tanin and associates showed that the conjunctival epithelium in patients stricken 
with GVHD reflects characteristic features of acute GVHD with infiltration of 
mononuclear cells expressing mature killer cells markers, suggesting that the 
pseudomembranous conjunctivitis associated with GVHD is the result of very acute 
cytotoxic form of GVHD.67 
          
Although pseudomembranous conjunctivitis is uncommon in GVHD, its presence 
has been considered a marker for systemic involvement and is associated with a poor 
prognosis.67 
   
 
Treatment of dry eye 
Medical Management 
       Preservative free artificial tears68 
       Methylcellulose eye drops69 
       Autologous serum drops70 
       Epidermal growth Factor71 
       Fibronectin72 
       Retinoic Acid73 
       Topical Steroids74 
       Tacrolimus74 
       Cyclosporine A75 can be used  
 
Systemic immunosuppressants such as cyclosporine (CsA) can be effective for 
treating ocular GVHD including lacrimal gland dysfunction.  However, systemic 
immunosuppression is not generally prescribed for patients whose sole manifestation of 
GVHD is ocular complications as it may negate the overall graft-vs-tumor effect and 
decrease the patient survival.  Topical Cyclosporine A is an immunomodulator.  The anti-
inflammatory effect arises largely from its ability to prevent the activation of T cells and 
the resulting production of cytokines and other inflammatory agents.  It is found to be 
useful in patients with severe dry eye.75 Some studies say that penetration of topical 
agents is not effective, therefore sustained release subconjunctival CsA implant has been 
developed to bypass these epithelial barriers and significantly increase the CsA 
concentrations in the lacrimal gland to treat aqueous tear deficiency related to GVHD.  A 
study on efficacy of cyclosporine implant in these patients is currently underway at 
Betesda in the USA.76  
  
Treatment of filamentary keratitis requires treatment of the underlying dry eye 
condition. Patients with severe symptoms frequently benefit form mucolytic agents (N - 
actylcysteine). 
  The management of persistent epithelial defects requires in addition to 
maximizing dry eye therapy, application of a bandage contact lens with judicious use of 
topical steroids with appropriate antibiotics to protect the compromised epithelium. 
Surgical intervention becomes necessary in selected cases of non healing epithelium or 
stromal disease which does not respond adequately to the recommended regimen.      
 
Surgical management  
  If the ocular surface involvement is severe or progressive , punctual occlusions 
should be considered.  There is a low threshold for the use of plugs in these patients as 
the plugs often dislodge early because of frequent rubbing of the eyes.  Heat cautery or 
laser punctal stenosis may be used as an alternative to achieve the desired degree of tear 
preservation and surface hydration. 77  
   
Tarsorrhaphy is a safe and time tested approach in these patients.  Evidence of 
corneal melting is an ominous sign that may require the use of tissue glue.  Multilayered 
amniotic membrane transplantation has been used to manage corneal perforation 
resulting form chronic GVHD. 
 
Cataract 
In additional to the ocular findings associated with compromised epithelium, 
cataract formation is common and can occur in 83% patients with long term follow up78 
Higher incidence is seen in those with GVHD probably due to use of long term 
corticosteroids.  The incidence of cataract is also high in patients who had undergone TBI 
and had used potentially cataractogenic chemotherapeutic agents such as Busulphan.79 
 
 Multivariate analysis showed that the total dose and the duration of corticosteroid 
therapy were the most important risk factor.  In another study the incidence of cataract 
was 2.3% at 2 years, but it did not cause significant visual impairment.80  The cataract 
was posterior subcapsular and surgery can be safely performed in GVHD patients.9 
Phacoemulsification with IOL is done with adequate preparation of the ocular surface  
including lubricants, punctal occlusion and topical anti inflammatory drugs.  
 
  Recurrent bilateral multifocal chorioretinitis with pan uveitis has also been 
noted.   Rarely patients may also present with uveitis which is thought to be a result of 
direct immunogenic attack of donor lymphocytes against host histocompatability 
antigens.  One rare case of scleritis with choroidal detachment as the initial clinical 
manifestation of acute GVHD on day 40 has been reported.26  
 
 
 
Posterior segment complications: 
A variety of complications can occur and they include microvascular retinopathy, 
intraretinal and vitreous hemorrhage and infections. 
CSR is an uncommon complication. 
 
  
 
 
 
                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
Study design: 
Descriptive, observational study   
Study population:  
Patients with aplastic anemia and various hematological malignancies that required SCT  
 
Inclusion criteria:  
Patients who had undergone bone marrow or peripheral blood stem cell transplant . 
  
Data collection:  
The principal investigator evaluated the patients for any ophthalmological complications  
The information was entered in the proforma.  
 
Methodology:  
The patients who had undergone SCT  had a complete ophthalmological examination.  
 
Vision:  Best Corrected visual acuity using Snellens chart and refraction. 
Lids   :  Examined for 
             Acute dermatitis /erythema with rash / generalized              
             erythroderma with blisters / desquamation  
             Chronic dermatitis diagnosed if there is ectropion /  
             lagophthalmos / scarring  
In the available literature, there is controversy regarding the criteria for diagnosis 
of dry eyes based on clinical diagnostic tests.  There is no gold standard for the diagnosis 
of dry eye.  A number of diagnostic tests have been described in the literature for 
evaluation of dry eyes.  All clinical tests have limited diagnostic value if performed 
individually or in the absence of severe symptoms.  It is not uncommon to find an 
abnormality of a single tear function test.  Thus for diagnosis of dry eyes more than one 
test should be abnormal. 
 
Dry eye: 
The tests done for the detection of dry eye  were 
              Schirmer’s test with paracaine 0.5% < 6mm at 5 minutes,   
               Debris in tear lake TBUT < 10 seconds and presence of thinning /    
               pannus  / filaments / ulcers .  
 
 
 
 
 
 
 
Definitions of the area and density grades of superficial punctate keratopathy on 
fluorescein staining  
Area (total sum of the affected area) 
A0:  no punctate staining 
A1:  area occupies less than one third of the cornea 
A2:  area occupies one third to two thirds of the cornea 
A3:  area occupies more than two thirds of the cornea 
Density 
D0:  no punctate staining 
D1:  sparse density 
D2:  moderate density 
D3:  high density and lesions overlap 
 
Criteria for diagnosis of dry eye   (At least 2/4 of the following criteria present) 
1. Tear lake  < 0.2mm / Tear debris 
2. Tear Break Up Time < 10 seconds 
3. Superficial punctate keratitis  
4. Schirmer’s test 1b 
 
Upper tarsal Conjunctiva:  
 Examined for signs of GVHD – Hyperemia / chemosis / pseudomembrane / epithelial    
loss and scarring.  
                       
Uveitis :        Diagnosed by presence of cells and flare in anterior chamber  
                      and / or vitreous  
Pupils:          Pupillary reflexes and presence of relative afferent pupillary defect 
IOP:              Measured by Goldmann’s applanation tonometer 
Cataracts:    Diagnosed by slit lamp examinations after dilatation with 1%     
                      tropicamide  
 
Grading   
Classified according to the Japanese Co operative Cataract Epidemiology Study Group 
System85 
Nuclear colour   
I    Pale yellow  
II  Yellow  
III Yellowish brown  
 IV Brown/ black  
 
 
 
Posterior subcapsular cataract   
 I    Opacity < normal pupil  
 II < moderate size pupil 
 III opacity > moderate sized pupil 
 
Dilated fundus :    Examination  with a  20D and 90D at slit lamp  
Disc:                    Examined for Glaucoma  
                             CDR>0 .7, Neuroretinal rim and                        
                             Nerve fibre layer defect, oedema, margins and SVP  
 
BMT Retinopathy: Cotton wool spots, telangiectasia, microaneurysm, macular      
                                    edema, hard exudates, hemorrhages.  
 
Infections:  CMV retinits, herpes zoster retinitis, fungus retinitis,        
       Toxoplasmosis and endopthalmitis.   
  
Hematological complications: Vitreous hemorrhage and intraretinal                                                              
                          hemorrhage.  
 
All patient included in this study would have undergone BMT according to the 
standard protocols used in Christian Medical College & Hospital, Vellore.  The 
preparative marrow ablative regimens were standardized according to the pre 
transplantation diagnosis 
 
In general the pre BMT conditioning for 
Acute Myeloid Leukaemia (AML) and Chronic Myelod Leukaemia (CML) 
  Intravenous IV Busulphan 16mg per kg total dose over 4 days plus 
 IV Cyclophosphamide 120mg per kg over 2 days . 
 
 Acute Lymphoid Leukaemia(ALL)   
 IV Cyclophosphamide 120mg per kg over 2 days plus     
 Total body irradiation 12 Gray over 3 days (2 Gray twice a                    
                                                                                         day with linear accelerator) 
 
Aplastic anemia 
                              .      IV Fludarabine 180mg per msq over 6 days plus 
 IV Cyclophosphamide 120mg per kg over 2 days +/- 
 Antithymocyte globulin 10mg per kg per day for 4 days. 
 
Thalassemia  
 IV Busulphan 16mg per kg total dose over 4 days plus  
 IV Cyclophosphamide 120mg per kg over 4 days and              
 Antithymocyte globulin 10mg per kg per day for 4 days 
 
TBI is given in acute lymphocytic leukemia and if there is CNS involvement. 
  
GVHD prophylaxis 
Cyclosporine IV 5mg per kg per day in divided doses for 3 to 6 months in leukemia and 
for one year in thalassemia and aplastic anemia plus  
Methotrexate 10mg per metre sq per day on day 1 and 7mg per metre sq per day on days 
3 , 6 and 11. 
IV Methylprednisolone 1mg per kg per day tapered over one month if the patient had 
jaundice. 
GVHD staging  
Skin GVHD graded according to the extent of involvement of the total body 
surface area.  Clinical staging of liver disease is based on the elevation of the liver 
enzyme and the bilirubin levels while staging of the gastrointestinal involvement is based 
on  the volume of diarrhea. 
 
Data Analysis :   Data entry was done using SPSS version. Statistical analysis was done 
using a Statistical Package STATA. 
Statistical Methods 
Statistical Methods employed in the study was the Chi Square Test to test the association 
between  
Dry eye and GVHD  
Systemic infections and ocular morbidity   
Dry eye in bone marrow compared to peripheral blood stem cell transplant 
Conjunctival GVHD in bone marrow compared to peripheral blood stem cell transplant. 
 
 
                                            Results 
 
A total of 40 patients who had undergone bone marrow and peripheral blood stem 
cell transplantation were studied.  The majority were males.  The mean age was 24.3 
years (SD 12.4).   The age range was from 5 to 51 years. 
 
Age wise grouping of patients who underwent transplantation is shown in the following 
table 
Table showing  age wise distribution of patients :Table 1 
 
   Age group  Number of      % 
patients            
< 10 years    7                17.5% 
11  -  20 years    7                17.5% 
21  -  30 years   12                30% 
31  -  40 years 10                25% 
41  -  50 years   3                7.5% 
>  51 years      1                2.5% 
 
In our study the majority of patients who underwent transplantation were below 
30 years of age.   
 
Transplant details  
Indications : 
Leukemias were the commonest indications for transplantation (table 2)  
The other indications were aplastic anaemia, thalassemia and myelodysplastic 
syndromes. 
 
Table showing distribution of indications for bone marrow transplantation: Table 2 
 
Indication for BMT Number of 
 patients                 %  
Leukemia      21              52.5% 
Aplastic anemia      6                15% 
Thalassemia      6                15% 
Myelo dysplastic syndrome            2                  5% 
Others *      5                12.5% 
 
• Others:, Paroxysmal Nocturnal Haemoglobinuria, High grade peripheral T cell 
lymphoma, Blackfan Diamond syndrome, Granulocytic sarcoma, Dyskeratosis 
congenita.  
 
 
 
 
 
Types of bone marrow transplantation: 
 
39/40 (97.5%) of the patients studied had allogenic transplantation. Only 1/40 
(2.5%) had autologous transplantation.  Majority  25/40 (62.5%) had Allogenic / 
PBSC/HLA matched transplantation.  
 
Table showing distribution of types of transplants :Table 3 
 
Type of  transplantation  Number of patients               % 
Allogenic / PBSC/HLA  Matched            25                             62.5% 
Allogenic / BMT/HLA  Matched            13                             32.5% 
Autologous /PBSC/ HLA  Matched             1                                2.5% 
Allogenic cord blood HLA Matched             1                               2.5% 
 
 
 
Conditioning: 
For conditioning prior to BMT 31/40 (77.5%) received chemotherapy and the 
remaining 9 (22.5%) received both, total body irradiation and chemotherapy.  These 
were based on standard protocols for each disease.  
 
 
Table showing distribution of conditioning regimen: Table 4 
 
 
Conditioning 
No 
of 
patie
nts 
    
     
% 
Chemotherapy alone 31 77% 
Chemotherapy & Total body irradiation 9 23%.
 
 
Engraftment 
The mean engraftment time was 19 days (SD 10.5).  The range was from 10 days 
to 69 days. 
Table showing distribution of engraftment time: Table 5 
 
Engraftment time  Number of patients               % 
< 10 days            1                              2.5% 
10 to 20 days             26                           65% 
21 to 30 days            10                            25% 
31 to 40 days             1                             2.5% 
> 40 days              2                            5% 
 
Infections  
50 % of the patients studied had systemic infection post BMT.  Bacterial sepsis 
was the commonest, seen in 11/40 (27.5%) patients.  8 /40 (20)% of patients had multiple 
sites of infection.  The remaining patients did not have any infection.  None of the 
patients had ocular infection. 
 
Systemic graft vs host disease   
24/40 patients (60%) of patients had developed systemic graft versus host  
disease ( GVHD).  18/40 (45%) had acute GVHD and 6/40 (15%) had chronic GVHD.  
 
Table showing distribution of sites involved in graft versus host disease (acute and 
chronic): Table 6 
 
Sites of GVHD    Number of patients               % 
Skin                   14                         58% 
Liver                   12  50% 
GIT                     8                         33% 
 
Skin was the commonest site involved in GVHD seen in 58% of the patients, 
followed by liver and then the gastrointestinal tract. 
 
 
 
 
 
Table showing distribution of multiple sites involvement in graft versus host disease: 
Table 7 
 
GVHD involving multiple sites Number of patients         %  
Skin and liver    5                                 12.5% 
Skin and GIT 2                                   5  % 
Liver and GIT 3                                  7.5% 
 
14 (35%) patients had GVHD involving only a single site while 10 (25%) had 
GVHD involving multiple organs (ie) skin, liver and GIT 
 
Ocular Morbidity in the post transplant period  
           26/40 (65%) patients had ocular morbidity following transplantation.  18/40 (45%) 
of the patients had more than one type of complication in the eye. 
  
Dry eye was the commonest ocular morbidity seen after transplantation seen in 
57.5% patients.  This was followed by Conjunctival GVHD in 35% of patients and 15% 
had cataract.  The cataracts were mostly grade one posterior subcapsular cataract.  Of the 
remaining 34 patients 2 patients were pseudophakic prior to the transplant.   Pre- existing 
vitreous hemorrhage and refractive error was seen in 7.5% each.  5% of patients had 
retinal complications like cystoid macular oedema and epiretinal membrane.    
 
 
Table showing distribution of patients with ocular morbidity: Table No: 8   
 
 Number of patients         % 
Dry eye    23                              57.5% 
Conjunctival GVHD    14                               35% 
Cataracts    6                                15% 
Vitreous Hemorrhage   3                                7.5% 
Refractive error   3                                7.5% 
Retinal changes   2                                 5% 
Lid changes   1                                2.5% 
 
* Retinal changes – ERM (epiretinal membrane), CME (cystoid macular edema) 
16/23 (69%) of the patients with dry eye had received chemotherapy as 
conditioning therapy while 7/23 (31%) patients had received both chemotherapy and 
radiation therapy.      
Only one patient had lid changes causing an ectropion.  None of the patients 
studied had  uveitis, pupillary abnormalities, raised intraocular pressures or ocular 
infections.  
 
Multiple ocular complications  
Few patients had multiple ocular complications as shown in Table 9.  The most 
common was dry eye associated with conjunctival GVHD seen in 32.5% of patients.  
This was followed by dry eye with cataract seen in 7.5% of patients.  One patient with 
vitreous hemorrhage had an associated dry eye and one patient had conjunctival GVHD 
with a pre existing vitreous hemorrhage.    
 
Table showing  distribution of multiple Ocular Complications Table No :9 
Multiple Ocular Complications No  of patients         % 
Dry eye + conj GVHD 13                            32.5% 
Dry eye + Cataract  3                              7.5% 
Dry eye + Vitreous Hemorrhage 1                              2.5% 
Conj GVHD + Vitreous Hemorrhage 1                              2.5% 
 
Visual Acuity 
             Visual impairment. ie Best Corrected Visual Acuity (BCVA) <6/6 was seen in 
37.5%.  Severe dry eye was the commonest cause seen in 20%.  These patients had 
BCVA varying from 6/36 to 6/6p.  Pre-existing refractive error and vitreous hemorrhage 
causing decrease in vision was noted in 7.5% each.  Two patients had retinal changes 
after the transplantation. 
 
Table showing distribution of causes of visual impairment Table No: 10  
Causes of visual impairment Total number   % 
Dry eye      8               20% 
Refractive error      3               7.5% 
Retinal change      2                5% 
Vitreous hemorrhage      3                7.5% 
 
Dry eye was the commonest ocular complication seen after transplantation.  Dry was 
also the commonest cause for visual impairment. 
 
Table showing distribution of criteria for dry eye   Table No :11 
 
Dry eye criteria   Total 23 patients 
Tear film Break Up Time<10 secs  23                            100% 
Tear lake<0.2mm\Tear Debris 20                              87% 
Superficial Punctate Keratitis 15                              65% 
Schirmer test I b 13                              56.5% 
Filamentary keratopathy 3                                13% 
Pannus 1                                4.3% 
 
All the patients with dry eye had an altered tear break up time.  A decreased tear 
lake with or without associated tear debris was the next most common finding in dry eye 
followed by superficial punctate keratitis.  Three patients had severe dry eye with 
filamentary keratopathy.    None of the patients studied had corneal thinning.   
 
All the patients with dry eye had a positive tear break up time less than 10 
seconds.  Of these patients more than 18/23 (78%) had at least three criteria positive for 
the diagnosis and 12/23 (52%)had four criteria positive for dry eye. 
 
Conjunctival GVHD 
Conjunctival GVHD was seen in 35% (14/40) of patients.  Hyperemia was the 
commonest manifestation.  Chemosis was not noted in any patient.   
Table showing distribution of manifestations of conjunctival GVHD 
 Table No: 12 
Conjunctival GVHD  Manifestations        
Hyperemia         8        20% 
Scarring         5        12.5% 
Epithelial loss and Pseudomembrane         1        2.5% 
 
Of the 14 patients who had conjunctival GVHD, 10 (75%) of them had an 
associated systemic GVHD.  
  
Table showing  distribution of interventions: Table No 13 
Intervention  Patients    % 
Lubricants 17           42.5% 
Lubricants + steroids 3              7.5% 
Lubricants +Punctal occlusions 2              5% 
Lubricants + cyclosporine 1              2.5% 
Vitrectomy  1              2.5% 
 
Most of the interventions were related to the treatment of dry eye.  All the patients 
with dry eye were given lubricants.  Three patients were given topical steroids in addition 
and two required punctal occlusion.  One patient was started on Cyclosporine drops.  One 
patient required a vitrectomy for a preexisting vitreous hemorrhage. 
 
Associations: 
The following associations were found on analysis: 
1. Increased occurrence of dry eye in patients who had developed systemic GVHD 
(p Value = 0.03) 
2. Increased ocular morbidity in patients with post transplant infections (p value = 
0.002).  
3. Same risk of developing dry with BMT and PBSCT (p value = 0.45) 
4. Same risk of developing conjunctival GVHD with BMT and PBSCT (p Value 
0.57) 
  
 
 
 
 
 
 
 
 
 
Table showing association between systemic  GVHD and dry eye - Table no: 14 
 
74% (17/23) of the patients who had dry eye had GVHD.  And 70% (17/24) of the 
patients who had GVHD had dry eye.  This association was found to be significant ( P 
Value = 0.03) 
 
 
 
 
 
 
 
 
 
 
Association between ocular morbidity and Systemic infections 
Table showing association between ocular morbidity and systemic infections 
2Table no: 15 
 Of the 26 patients who had ocular morbidity,15 patients (57%) had infection in  the post 
transplant period.  Of the 20  patients who had  infection in the post transplant period 15 
(75%) had developed some ocular morbidity . This associataion was significant p value = 
0.002 .  
 
 
 
 
 
 
 
 
 
 
 
 
Association between dry eye in BMTvs PBSCT  
 
Table showing association between dry eye in BMTvs PBSCT  - Table 16  
 
 
 
 
Dry eye was seen in 7/14 (50%) of the patients who had undergone bone marrow 
transplantation. In those who had PBSCT dry was seen in 15/24 (62.5%).  The difference 
between these two groups was not significant P value = 0.45  
 
 
 
 
 
 
 
 
 
Association between conjunctival GVHD in BMTvs PBSCT 
Table showing association between conjunctival GVHD in BMTvs PBSCT 
Table 17 
  
Conjunctival GVHD was seen in 4/13 (30.7%) patients who had undergone bone marrow 
transplantaion while this was seen in 10/25 (40%) patients who had undergone PBSCT .  
The difference between these two groups was not significant, p Value 0.57 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 Bone marrow and peripheral blood stem cell transplantation is a life saving 
procedure for an increasing number of patients.  With the advent of immunology, 
histocompatibility testing, immunosuppressive therapy and good supportive care the pool 
of suitable donor marrow expands from autologous grafts to include HLA matched 
related individuals and fully / partially matched unrelated individuals.  This increases the 
chance of more patients benefiting from SCT.  This will result in an increased number of 
long-term survivors who will need specialised monitoring and management for the 
various post transplant complications and morbidity. 
 
We studied 40 patients in the post transplant period who had BMT or PBSCT 
done in our hospital.  Ocular morbidity was seen in 65% of them.  These morbidity could 
be broadly classified as Ocular surface diseases – dry eye(57.5%), conjunctival 
GVHD(35%), cataracts(15%) and retinal changes( 5%). 
 
As conditioning regimen prior to transplantation 77% received chemotherapy 
alone and the rest 23% had both radiation and chemotherapy.  Sullivan  had shown a 
higher incidence of dry eye in patients receiving radiotherapy in addition to 
chemotherapy for conditioning.84  In our study  77% of the patients who had received 
radiation prior to the transplant had developed dry eye while this was seen in 53% who 
had received only chemotherapy.  But the number of patients who received chemotherapy 
and radiation were only nine compared to 31 who had only chemotherapy and hence an 
association could not be established.     
 
In our study population 97% had allogenic transplants (allogenic PBSCT in 
62.5% and allogenic BMT in 32.5%).  Lawrence et al have shown that allogenic PBSCT 
has an increased incidence of systemic GVHD.4 Ocular morbidity like dry eye and 
conjunctival GVHD is seen more in patients with systemic GVHD.26 However we could 
not find a statistically significant difference in the incidence of either dry eye or 
conjunctival GVHD in patients who had allogenic PBSCT vs allogenic BMT in our 
study. ( p values 0.45 and 0.57 respectively.) 
 
Ocular surface disease is the most prevalent problem after haematopoietic stem 
cell transplantation.  Of the 65% (26/40) of patients with ocular morbidity, the majority 
of them ie 57% (23/40) were noted to have findings suggestive of dry eye.  Jack and 
Hicks have noted dry eye syndrome in 40 out of 90 patients.  However they have not 
mentioned how many of their patients had developed GVHD.82 In another study by 
Kenyon et al the incidence of dry eye was as high as 60% in patients with GVHD.68  
This developed three months after BMT and included dry eye with corneal sequelae 
causing punctate keratitis, persistent epithelial defect, and sterile /infectious stromal 
ulceration.  This illustrates the fact that dry eye is more often seen in patients with 
chronic GVHD and that the severity of dry eye is also more when the patient has GVHD.   
 
The age of the patients ranged from 5 to 51 years.  Of the seven patients less than 
10 years of age, only one of them had dry eye.  This is in keeping with a study which 
proved that the prevalence of dry eye syndrome is less in children than in adults owing to 
healthier and faster regeneration of epithelial cells.3  However the number of children in 
our study was too small to establish a statistical significance.  
 
None of the patients developed persistent epithelial defect, sterile or infectious 
stromal ulceration.  Most of the patients as in other studies responded to topical ocular 
lubricants.  Out of 40, three required topical steroids and two required punctal occlusion.  
Only one patient was given topical cyclosporine.  The long term efficacy of cyclosporine 
drops in treatment of dry eye in GVHD has to be evaluated on follow up. 
 
None of the patients required a major surgical intervention like Tarrsoraphy, 
conjunctival homograft, amniotic membrane transplantation or penetrating keratoplasty. 
 
In this study there was a significant association between development of dry eye 
and presence of GVHD (p value 0.03).  This finding has been reported in other studies.4 
Our study also showed a significant association between ocular morbidity and 
systemic infections in the immediate post transplant period.    However the exact reason 
for this could not be ascertained.  Literature search did not reveal an increased incidence 
of ocular morbidity in the presence of systemic infections in other studies.   
 
 
Conjunctival GVHD  
 Conjunctival GVHD is a marker for severe systemic GVHD and development of 
higher stage of ocular GVHD was found to be significantly associated with more severe 
forms of both acute and chronic systemic GVHD.7 In this study of the 14 patients who 
had conjunctival GVHD, 10 (75%)of them had an associated systemic GVHD. 
 
Jabs et al have reported the incidence of conjunctival GVHD to be 12% in acute 
GVHD and 11.1% in chronic GVHD.19   In the above study, most patients presented with 
pseudomembrane - grade 3 conjunctival GVHD.  This is in contrast to our study where  
conjunctival GVHD was seen in 35% patients and the commonest finding was hyperemia 
of the conjunctiva - grade 1 conjunctival GVHD.   Only one patient had a 
pseudomembrane formation which is a higher grade of conjunctival GVHD. 
           .   
Cataract 
 Cataract formation is common in allogenic stem cell transplant patients52,78,79 
occurring in as many as 83% with long term follow up.78   There is an association between 
cataract and GVHD which is said to be due to the use of long term corticosteroids.  In 
addition pre transplant TBI conditioning is also associated with higher incidence of 
cataract.   
 
Cataract was noted in 15% of our patients and all of them had grade 1 posterior 
subcapsular cataract.  As we had not seen the patients prior to transplantation we could 
not attribute the cataract to transplantation.  Two patients were pseudophakic prior to the 
transplant..   
 
Cataract surgery with intraocular lens implantation can be safely performed in 
GVHD patients.9   Preoperative ocular surface rehabilitation, including lubricants, punctal 
occlusion and topical anti-inflammatory agents is essential to reduce the incidence of 
complications after the surgery. 
 
Posterior segment complications  
            Incidence of posterior segment complications post haematopoietic stem 
cell transplantation has been reported to be around 12%.30  These complications although 
rare,  can have significant visual consequences and implications.  In our study only 2 of 
the patients (5%) developed posterior segment complications.  One had cystoid macular 
edema and the other had epiretinal membrane.  Cystoid macular oedema has not been 
described in the literature in post transplant recipients.  None of the patients developed 
BMT retinopathy/ retinal infections or optic disc oedema. 
 
Three patients had pre existing vitreous hemorrhage prior to SCT.  This could be 
secondary to the disease or thrombocytopenia occurring after chemotherapy.  
           
 
 
 
 Miscellaneous Findings 
The cutaneous manifestations of GVHD can affect the eyelids.  Dermatitis, 
lagophthalmos, ectropion, poliosis, madarosis, vitiligo can occur. Only one of our 
patients developed an ectropion.  This was secondary to the skin GVHD that the patient 
had. 
The first and major limitation of our  study was that it involved only a subset of 
patients who were well enough or were willing to come for an ophthalmic evaluation and 
hence did not include all the patients who had come for a review post transplant.  
Therefore the profile of ocular morbidity described may not be accurate.    
 
We do not know the pre BMT status of the patient. This is important because the 
conditions requiring transplantation such as leukaemias and anaemias by themselves are 
associated with significant ocular morbidity due to the associated anaemia, 
thrombocytopenia and polycythaemia. 
   
The acute ocular complications could not be ascertained because the patients were 
not evaluated in the immediate post transplant period.  This was due to the fact that they 
were under barrier nursing or they were acutely ill to undergo a thorough ophthalmologic 
evaluation.    
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
• 65% of the patients post bone marrow and peripheral blood stem cell 
transplantation  had ocular morbidity. 
• Dry eye (57.5%) was the commonest finding followed by conjunctival GVHD 
(35%) and posterior subcapsular cataract(15%).  
• Increased incidence of ocular morbidity is seen in patients with post transplant 
infections . 
• Increased occurrence of dry eye is seen in patients who had developed systemic 
GVHD 
• The  risk of developing dry eye is the same in patients who have had BMT and in 
those who had PBSCT  
• The risk  of developing conjunctival GVHD is the same in patients who have had 
BMT and in those who had PBSCT  
 
Regular ophthalmic examination is therefore essential especially for patients who 
have had systemic infections and or systemic graft versus host disease for early detection 
and treatment of the potential complications. 
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The diagnostic tests for dry eye are the Schirmer test, Tear break up time, Tear 
meniscus height and tear debris and Fluorescein staining of the cornea. 
(1 ) Schirmer test:  Measures the quantity of the tears produced by the    
eye.62 
 
Schirmer Ia:  Tests basic and reflex secretions. 
A standardized strip of filter paper (Whatman No:41) is placed in the eye.  The patient is 
instructed to look forward and to blink normally during the course of the test.  After 5 
minutes the filter paper is removed and the length of the moistened part is measured.  
Less than 5mm of wetting is suggestive of  dry eye. 
 
Schirmer Ib :  
The same test is done after instilling local anesthetic.  This measures mainly the 
basal secretion.  The reflex secretion is not completely abolished by this test.  Less than 
5mm at 5 minutes is suggestive of dry eye.   
 
(2)Tear break up time 
A drop of fluorescein is instilled in the eye, time in seconds between  the last 
blink and the first randomly distributed dry spot is noted under slit lamp with cobalt blue 
illumination.63  Ten seconds is the normal cutoff for TBUT. 
It is a specific test for mucin deficiency.  Limitations are that  erratic results occur 
in the absence of standard conditions and corneal surface irregularities affect accurate 
measurements. 
  
(3) Fluorescein staining of the cornea.  
 Fluorescein staining manifests  where cell to cell junctions are disrupted.64t lacks 
the ability to be blocked by tear constituents and diffuses rapidly into the stroma   It acts 
as a vital stain adhering to devitalized cells.  The area and density of staining is measured 
and graded. 
 
(4) Tear meniscus: 
Height of less than 0.2mm / presence of debris is suggestive of dry eye.65 
Various studies have taken one or more of the above tests to diagnose dry eye. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proforma 
 
Ocular complications in Bone marrow and peripheral blood 
stem cell transplantation  
 
 
Hospital number : Schell      CMCH 
 
Name         Address  
 
DOB    Age     Sex  Male  Female 
 
Diagnosis   
 
AML / ALL / CLL / CML  
Aplastic anemia 
Thalasaemia  
 
Pre BMT  conditioning  :   TBI / Chemotherapy / Both 
 
GVHD Prophylaxis : Cyclosporine + Methotreaxate  / Cyclosporine + 
Methylprednisolone 
 
BMT :  Date  
 Type  Allogenic /Syngenic/ Autogenic 
                        PBSC /BMT / CB 
Time of engraftment-ANC/platelet count 
Systemic complications:  
 
Infections :  
Date  
Type  - fungal / bacterial / viral / parasitic  
Investigations – blood culture / urine / pus /CXR / BAL / PCR / clinical/ others  
Treatment : antibiotics /antifungals /antiparasitic /  
Number of days  
 
GVHD  
 Present / absent 
 Time of onset 
 Acute /chronic / acute on chronic  
 Clinical features – skin (01234) / liver   (01234)    /GIT   (01234)   /  
  Treatment – Steroids / Cyclosporine /Methotrexate  
  Investigations – PCV /Hb / MCHC / BP / LFT / PT /PTT   Date 
 
 
 
 
 
 
 
 
 
OPHTHALMIC EVALUATION 
 
                                                Pre date             Post I date          Post II date  
                                                 R     L               R         L             R         L  
 
 
Visual acuity  Unaided 
                        BCVA 
                        Ref error 
 
Lids Acute       Erythema  
Dermatitis        Blisters  
                         Desquamation 
 
Chronic  
Dermatitis       Ectropion      
                        Lagopthalmos 
                        Scarring  
  
 
Dry eye            Tear lake  
                         Schirmer test 
                         TBUT 
 
                        SPK A/D   
                        Thinning 
                        Pannus 
                        Filaments 
  Ulcer infectious / sterile  
 
Upper Tarsal 
Conjunctiva     Hypermia 
  Chemosis 
  Pseudomembrane  
  Epithelial loss 
  Scarring 
 
Uveitis  Anterior 
  Posterior 
  Pan 
Pupil  RAPD 
  IOP 
 
Cataract          NS I/II/III/IV 
            PSC I/II/III         
 
 
BMT  
Retinopathy  
 
infections  CMV 
  HZ 
  Fungal 
  Toxo 
  Endopthalmitis 
 
Hematologic    VH 
                         IR Hg 
CSR 
ERM 
 
Others  
 
Intervention     Nil  
                        Lubricants 
                        Cyclosporine 
                        Punctual occlusion 
                        Tarrsoraphy 
                         Others 
 
 
Examiner’s notes: 
 
Ophthalmological diagnosis : 
 
 
